Find trials
Search tips

Probiotic in Patients with Bile Acid Malabsorption/Diarrhea

Overview

About this study

The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

 Inclusion Criteria:

  • Adults ≥ 18 years diagnosed with bile acid malabsorption based on either serum C4 > 52.5ng/mL, or fecal 48h total BA excretion > 2337 μmol/48h, or primary BA > 5% in single or 48h stool collection.
  • Stable disease after limited intestinal resection for neuroendocrine (carcinoid) tumor, not receiving chemo- or radiotherapy  

Exclusion Criteria:

  • Use of antibiotics or probiotics within the last 4 weeks.
  • Pregnancy or lactation.
  • Concomitant use of bile acid sequestrants

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/15/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Camilleri, M.D., D.Sc.

Open for enrollment

Contact information:

Monique Ferber

(507) 538-6599

Ferber.Monique@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20573392

Mayo Clinic Footer